Dr. Kazuaki Takabe, MD, PhD

Dr. Takabe practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. Takabe's NPI, 1942460126, was assigned on June 11, 2008. Dr. Takabe holds New York license 284620.

Dr. Takabe's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. Takabe's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. Takabe is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Takabe practices. Vendor and product names are available with a free account.

Surgery is Dr. Takabe's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Takabe is licensed in New York.

CMS data shows 17 Medicare services from Dr. Takabe across 1 procedure code in 2024, for 33 Medicare patients. Medicare paid $8,267 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 33 Medicare patients who saw Dr. Takabe in 2024. The largest group is 65 to 74, with 14 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Takabe's median patient age at 70, with 99% women.

In 2023, Dr. Takabe wrote 15 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $605 in total drug cost. In 2018, CMS named 17 claims across 1 drug.

Dr. Takabe accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 37 procedures of mastectomy by Dr. Takabe, more than 90% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 345 papers to Dr. Takabe, published from 2010 to 2025. 2021 was the busiest year, with 45. The most frequent topics are Breast Neoplasms, Gene Expression Regulation, Neoplastic and Biomarkers, Tumor. Dr. Takabe has published most often in Am J Cancer Res. Dr. Takabe's most frequent co-authors are Omar Maen Rashid, JD, MD, Shipra Gandhi, MBBS and Arya Mariam Roy, MD.

Dmand AI links Dr. Takabe to 2 clinical trials, 2 of them phase 2 studies. Conditions studied include Breast Neoplasms, Carcinoma, Ductal, Breast and Breast Diseases.

CMS Open Payments shows 27 general payments to Dr. Takabe from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Genentech, Inc. paid the most, $9,022.